scholarly journals Pharmacological Effects of Favipiravir on Coronavirus: An Update

2021 ◽  
Vol 14 (02) ◽  
pp. 1087-1095
Author(s):  
Prerna Tejaswi ◽  
Kumar Devashish ◽  
Raj Ranjan Prasad
Keyword(s):  
Research And Development ◽  
Broad Spectrum ◽  
Safety Profile ◽  
Treatment Options ◽  
Specific Treatment ◽  
Antiviral Drugs ◽  
Review Article ◽  
Pharmacological Effects ◽  
Health Crisis ◽  
Novel Virus

The coronavirus pandemic is the worst health crisis of our time. There is a massive upsurge of the cases and no specific treatment options of this novel virus (SARS-CoV-2).Due to no time for research and development of a new drug or a vaccine, old and existing broad spectrum antiviral drugs were tried and tested. Favipiravir showed promising results in mild to moderate COVID-19 infection in small studies. The drug is approved with precaution under emergency use, as its safety profile is still not clear. We have considered every aspect of favipiravir and compiled all the latest information about the drug in this review article.

The chronicle of COVID-19: possible strategies to curb the pandemic

2020 ◽  
Vol 27 ◽  
Author(s):  
Rajesh Kumar ◽  
Seetha Harilal ◽  
Abdullah G. Al-Sehemi ◽  
Githa Elizabeth Mathew ◽  
Simone Carradori ◽  
...  
Keyword(s):  
Life Cycle ◽  
Research And Development ◽  
Vaccine Development ◽  
Therapeutic Strategies ◽  
Antiviral Drugs ◽  
Limited Data ◽  
Social Distancing ◽  
The World ◽  
Novel Virus ◽  
Day By Day

: COVID-19, an epidemic that emerged in Wuhan, has become a pandemic affecting worldwide and is in a rapidly evolving condition. Day by day, the confirmed cases and deaths are increasing many folds. SARS-CoV-2 is a novel virus; therefore, limited data are available to curb the disease. Epidemiological approaches, isolation, quarantine, social distancing, lockdown, and curfew are being employed to halt the spread of the disease. Individual and joint efforts all over the world are producing a wealth of data and information which are expected to produce therapeutic strategies against COVID-19. Current research focuses on the utilization of antiviral drugs, repurposing strategies, vaccine development as well as basic to advanced research about the organism and the infection. The review focuses on the life cycle, targets, and possible therapeutic strategies, which can lead to further research and development of COVID-19 therapy.

scholarly journals Potential Antiviral Options against SARS-CoV-2 Infection

Viruses ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 642 ◽  
Author(s):  
Aleksandr Ianevski ◽  
Rouan Yao ◽  
Mona Høysæter Fenstad ◽  
Svetlana Biza ◽  
Eva Zusinaite ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Broad Spectrum ◽  
Treatment Options ◽  
Neutralization Assay ◽  
World Health ◽  
The World ◽  
Emerging Treatments ◽  
Novel Virus ◽  
Health Organization ◽  
Respiratory Coronavirus

As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.

scholarly journals The Pathophysiology of Repurposed Antiviral Drugs for treatment of COVID-19 Infection

2020 ◽  
Vol 1 (supplement) ◽  
pp. 6
Author(s):  
Adnan Haider ◽  
Muhammad Faheem ◽  
Sayed Babar Jamal ◽  
Muhammad Naeem ◽  
Atif Ali Khan Khalil ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Chemical Structure ◽  
Virus Disease ◽  
Rna Virus ◽  
Neurological Complications ◽  
Antiviral Drugs ◽  
Review Article ◽  
Republic Of China ◽  
Positive Sense ◽  
Novel Virus

Our planet earth has seen many viral pandemics The most recent pandemic was Severe Acute Respiratory Syndrome (SARS-CoV-2) commonly called Corona Virus disease (COVID-19). It was first reported inWuhan Peoples Republic of China, in December 2019. COVID-19 is a positive-sense single-strand enveloped RNA virus mainly found in mammals. To date, a total of six species of coronavirus have been reported that affected humans. These mainly cause respiratory, hepatic, enteric, and neurological complications. Since it is a novel virus, different therapies were used for the treatment These measures comprised of mostly repurposing of already available drugs, more specifically antiviral drugs. In this review article, we have summarized the virus- host relation and chemical structure and also discussed in detail the proposed mechanism of these repurposed antivirals drugs.

scholarly journals Potential antiviral options against SARS-CoV-2 infection

2020 ◽  
Author(s):  
Aleksandr Ianevski ◽  
Rouan Yao ◽  
Mona Høysæter Fenstad ◽  
Svetlana Biza ◽  
Eva Zusinaite ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Broad Spectrum ◽  
Treatment Options ◽  
Neutralization Assay ◽  
World Health ◽  
The World ◽  
Emerging Treatments ◽  
Novel Virus ◽  
Health Organization ◽  
Respiratory Coronavirus

AbstractAs of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6,5 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified most potent sera from recovered patients for treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that combinations of virus-directed nelfinavir along with host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.

A Review Article on the Therapeutic Potential of Medicinal Plants for Prevention and Treatment of secondary infection in patients with COVID-19

2021 ◽  
Vol 08 ◽  
Author(s):  
Swati Rathore ◽  
Richa Tripathy Tiwari ◽  
Neha Rai ◽  
Debarshi Kar Mahapatra ◽  
Shailendra Patil ◽  
...  
Keyword(s):  
Medicinal Plants ◽  
Therapeutic Potential ◽  
Secondary Infection ◽  
Antiviral Drug ◽  
Specific Treatment ◽  
International Health ◽  
Review Article ◽  
Health Crisis ◽  
Treatment And Prevention ◽  
Herbal Formulations

: COVID-19 is an infectious disease, caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) that is rapidly spreading all over the world and responsible for the international health crisis. In an earlier period, various synthetic antiviral drugs and clinical therapies have been used to control the viral infection but at present, there is no specific treatment available for COVID-19 infection. Several approaches like ritonavir, lopinavir, hydroxychloroquine, and chloroquine have been proposed. India is a hub of medicinal plants, so there is a chance to find out the way to combat the COVID-19 pandemic. The medicinal herbal formulations may enhance the immunity and come up with a powerful antiviral drug, which is an urgent need to control the outbreak of coronavirus. In this review article, we have discussed epidemiology, clinical outcomes, treatment, and prevention of this novel epidemic coronavirus from medicinal herbal formulations perspective. We have also emphasized the reported antiviral activity and immunity-boosting property of the Indian medicinal plants. This article also suggests that the drug or formulation obtained from medicinal plant sources may have low fatal outcomes, quick response, and safe in the management and prevention of this pandemic outbreak.

scholarly journals Pharmacology and Ethnomedicine of the Genus Astragalus

2016 ◽  
Vol 3 ◽  
pp. 46-53 ◽  
Author(s):  
Roman Lysiuk ◽  
Roman Darmohray
Keyword(s):  
Medicinal Plants ◽  
Broad Spectrum ◽  
Antiviral Agents ◽  
Folk Medicine ◽  
Pharmacological Action ◽  
Scientific Data ◽  
Review Article ◽  
Pharmacological Effects ◽  
Herbal Drugs ◽  
Morphological Distribution

The genus Astragalus, consisting of about 3000 species, is a valuable source of herbal drugs. The review article comprises scientific data concerning morphological, distribution and phytochemical characters of the genus. Polysaccharides, saponins, and flavonoids are considered main active principles. Astragalus spp. have long been used as medicinal plants in folk medicine as cardiovascular, antihypertensive, diuretic, choleretic, as well as antimicrobial and antiviral agents. The plants of the genus exhibit a broad spectrum of pharmacological effects, among which major include diuretic, anti-inflammatory, bactericidal, hypotensive, and sedative ones. The review focuses on uses of about 30 Astragalus species in official medicine and ethnomedicine and their pharmacological action.

The Plausible role of Indian Traditional Medicine in combating Corona Virus (SARS-CoV 2): a mini-review

2020 ◽  
Vol 21 ◽  
Author(s):  
Adithya J ◽  
Bhagyalakshmi Nair ◽  
Aishwarya S ◽  
Lekshmi R. Nath
Keyword(s):  
Specific Treatment ◽  
Ocimum Sanctum ◽  
Drug Candidate ◽  
Asparagus Racemosus ◽  
Traditional System ◽  
Traditional Medicines ◽  
Contagious Nature ◽  
Community Transmission ◽  
Novel Virus

: SARS-CoV 2 is a novel virus strain of Coronavirus, reported in China in late December 2019. Its highly contagious nature in humans has prompted WHO to designate the ongoing pandemic as a Public Health Emergency of International Concern. At this moment, there is no specific treatment and the therapeutic strategies to deal with the infection are only supportive, and prevention aimed at reducing community transmission. A permanent solution for the pandemic, which has brought the world economy to the edge of collapse, is the need of the hour. This situation has brought intense research in traditional systems of medicine. Indian Traditional System, Ayurveda has a clear concept of the cause and treatment of pandemics. Through this review, information on the potential antiviral traditional medicines along with their immunomodulatory pathways is discussed. We have covered the seven most important Indian traditional plants with antiviral properties :Withaniasomnifera (L.) Dunal(family: Solanaceae),Tinosporacordifolia(Thunb.)Miers (family:Menispermaceae),Phyllanthusemblica L.(family:Euphorbiaceae),Asparagus racemosus L.(family:Liliaceae), Glycyrrhizaglabra L.(family:Fabaceae), Ocimum sanctum L.(family:Lamiaceae) and Azadirachta indica A.Juss(family:Meliaceae)in this review. An attempt is also made to bring into limelight the importance of dietary polyphenol, Quercetin which is a potential drug candidate in the making against the SARS-CoV2 virus.

Nucleosides and Nucleoside Analogues as Emerging Antiviral Drugs

2020 ◽  
Vol 17 ◽  
Author(s):  
Mohamed Ibrahim Elzagheid
Keyword(s):  
Significant Role ◽  
Mode Of Action ◽  
Crucial Role ◽  
Viral Infections ◽  
Antiviral Drugs ◽  
Review Article ◽  
Nucleoside Analogues ◽  
The Past ◽  
Nucleoside Drugs

: Nucleosides and their analogues have been in use for many years and have become essential for treating patients with viral infections. Many additional nucleoside drugs have been approved over the past decades. This strongly demonstrates how important these compounds are and the crucial role they play. Given that a significant amount of research and literature has been documented regarding nucleoside analogues, this review article mainly focuses the discussion on nucleosides and nucleoside analogous that have proven to play significant role or be emerging in the treatment of known viral infections. This covers the names, structures, applications, toxicity, and mode of action of relevant nucleoside analogues.

scholarly journals Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma

2021 ◽  
Vol 10 (13) ◽  
pp. 2803
Author(s):  
Carolin Czauderna ◽  
Martha M. Kirstein ◽  
Hauke C. Tews ◽  
Arndt Vogel ◽  
Jens U. Marquardt
Keyword(s):  
Clinical Care ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Specific Treatment ◽  
Growth Factor Receptor ◽  
Treatment Modalities ◽  
Precision Oncology ◽  
Recurrence Rates ◽  
Isocitrate Dehydrogenase 1 ◽  
Liver Cancers

Cholangiocarcinomas (CCAs) are the second-most common primary liver cancers. CCAs represent a group of highly heterogeneous tumors classified based on anatomical localization into intra- (iCCA) and extrahepatic CCA (eCCA). In contrast to eCCA, the incidence of iCCA is increasing worldwide. Curative treatment strategies for all CCAs involve oncological resection followed by adjuvant chemotherapy in early stages, whereas chemotherapy is administered at advanced stages of disease. Due to late diagnosis, high recurrence rates, and limited treatment options, the prognosis of patients remains poor. Comprehensive molecular characterization has further revealed considerable heterogeneity and distinct prognostic and therapeutic traits for iCCA and eCCA, indicating that specific treatment modalities are required for different subclasses. Several druggable alterations and oncogenic drivers such as fibroblast growth factor receptor 2 gene fusions and hotspot mutations in isocitrate dehydrogenase 1 and 2 mutations have been identified. Specific inhibitors have demonstrated striking antitumor activity in affected subgroups of patients in phase II and III clinical trials. Thus, improved understanding of the molecular complexity has paved the way for precision oncological approaches. Here, we outline current advances in targeted treatments and immunotherapeutic approaches. In addition, we delineate future perspectives for different molecular subclasses that will improve the clinical care of iCCA patients.

scholarly journals 549. Clinical Characteristics and Outcomes of Patients with COVID-19 treated with Convalescent Plasma in Miami, Florida

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S340-S341
Author(s):  
Shweta Anjan ◽  
Dimitra Skiada ◽  
Miriam Andrea Duque Cuartas ◽  
Douglas Salguero ◽  
David P Serota ◽  
...  
Keyword(s):  
Treatment Options ◽  
Disease Outbreaks ◽  
Nasopharyngeal Swab ◽  
Rt Pcr ◽  
Health Crisis ◽  
Infectious Disease Outbreaks ◽  
Reactive Protein ◽  
High Acuity ◽  
Us Fda ◽  
Oxygen Requirements

Abstract Background The Coronavirus disease of 2019 (COVID-19) global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in unprecedented mortality, impacted society, and strained healthcare systems, yet sufficient data regarding treatment options are lacking. Convalescent plasma, used since 1895 for infectious disease outbreaks, offers promise as a treatment option for COVID-19. Methods This is a retrospective study of patients diagnosed by a nasopharyngeal swab SARS-CoV-2 reverse transcriptase–polymerase chain reaction (RT-PCR), who received convalescent plasma between April to June 2020 at two large hospitals in Miami, Florida, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma (CCP). Results A total of 23 patients received CCP, 13 (57%) had severe COVID-19 disease, while 8 (35%) had critical or critical with multiorgan dysfunction. Median time of follow up was 26 (range, 7–79) days. Overall, 11 (48%) survived to discharge, 6 (26%) died, while 6 (26%) are currently hospitalized. All deaths reported were due to septic shock from secondary infections. 15 (65%) showed improvement in oxygen requirements 7 days post CCP transfusion. Measured inflammatory markers, c-reactive protein, lactate dehydrogenase, ferritin and d-dimer improved 7 days post transfusion in 13 (57%) patients. No adverse events due to the transfusion were reported. 10 (43.4%) patients had a negative SARS-CoV-2 RT-PCR at a median of 14.5 (range, 4–31) days after receiving convalescent plasma. Conclusion Administration of convalescent plasma was found to be safe, with favorable outcomes in this small cohort of relatively high acuity patients. Larger studies including control arms are needed to establish the efficacy of convalescent plasma on clinical and virologic outcomes for patients with COVID-19. Table Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document